Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

Key Takeaways

• Moderna’s CEO Stéphane Bancel sees opportunity in BioNTech’s planned closures of sites in Idar‑Oberstein, Marburg, Tübingen and Singapore, as a potential shortcut to expand production capacity rather than constructing new facilities (biontech.com)
• BioNTech intends to close multiple manufacturing sites by end‑2027 to cut costs amid declining COVID‑19 vaccine demand—affecting up to 1,860 roles and projected to yield annual savings of about €500 million from 2029, redirecting resources toward oncology R&D (biontech.com)
• This move by Moderna aligns with Europe’s need to maintain mRNA manufacturing resilience, as voiced by public health experts concerned that BioNTech’s exit could leave continental Europe without local mRNA vaccine infrastructure (onvista.de)